Clinical trial · Observational
PD-L1 Expression in Advanced Osteosarcoma
The Expression of Programmed Death Ligand-1 (PD-L1) on Advanced Osteosarcoma Tissue and Its Influence on Prognosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Progression | — | UNRESOLVED | — |
| Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| all study participants | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- observation group
- description
- All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
- interventionNames
- Other: all study participants
Primary outcomes (1)
- measure
- PD-L1 expression level
- timeFrame
- 2 months
- description
- all those specimens will be tested for expression level,Tumors with ≥50% cells showing positive membrane staining were considered to have high expression of PD-L1
Secondary outcomes (2)
- measure
- progression free survival
- timeFrame
- 2 years
- description
- from the timing of testing to disease progression/death whichever comes first
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * diagnosis confirmed histologically and reviewed centrally; * received surgery in Musculoskeletal Tumor Center of Peking University People's Hospital with appropriate sample for immunohistochemical staining; * progressing upon prior treatment (completed \>4 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide; metastatic relapsed and unresectable progressive disease (PD); * having measurable lesion according to RECIST 1.1; * Eastern Cooperative Oncology Group performance status 0-1 with a life expectancy \>3 months; * intend to receive anti-PD-1/anti-PD-L1 antibody for therapy. Exclusion Criteria: * fail to be followed up regularly. * sample disqualification.
References
Publications (0)
Data not yet available